|
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
PR Newswire (press release) BOULDER, Colo., July 23, 2013 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced positive results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial After-market Movers For July 22 (NFLX, TXN, SANM, ARRY) |
View full post on asthma – Google News